Drug Augmentation Strategies for Treatment- Resistant Obsessive- Compulsive and Related Disorders
Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
bookPart
Data de publicação
2019
Título da Revista
ISSN da Revista
Título do Volume
Editora
CAMBRIDGE UNIVERSITY PRESS
Autores
Citação
Shavitt, R. G.; Diniz, J. B.. Drug Augmentation Strategies for Treatment- Resistant Obsessive- Compulsive and Related Disorders. In: . A TRANSDIAGNOSTIC APPROACH TO OBSESSIONS, COMPULSIONS AND RELATED PHENOMENA: CAMBRIDGE UNIVERSITY PRESS, 2019. p.229-241.
Resumo
Palavras-chave
Referências
- Bandelow, B., Zohar, J., Hollander, E., World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders-first revision (2008) World J Biol Psychiatry, 9 (4), pp. 248-312
- Hollander, E., Allen, A., Kwon, J., Clomipramine vs desipramine crossover trial in body dysmorphic disorder: Selective efficacy of a serotonin reuptake inhibitor in imagined ugliness (1999) Arch Gen Psychiatry, 56 (11), pp. 1033-1039
- Johnson, J., El-Alfy, A.T., Review of available studies of the neurobiology and pharmacotherapeutic management of trichotillomania (2016) J Adv Res, 7 (2), pp. 169-184
- Brakoulias, V., Eslick, G.D., Starcevic, V., A metaanalysis of the response of pathological hoarding to pharmacotherapy (2015) Psychiatry Res, 229 (1-2), pp. 272-276
- Mataix-Cols, D., Fernández de la Cruz, L., Nordsletten, A.E., Lenhard, F., Isomura, K., Simpson, H.B., Towards an international expert consensus for defining treatment response, remission, recovery and relapse in obsessive-compulsive disorder (2016) World Psychiatry, 15 (1), pp. 80-81
- Belotto-Silva, C., Diniz, J.B., Malavazzi, D.M., Group cognitive-behavioral therapy versus selective serotonin reuptake inhibitors for obsessive-compulsive disorder: A practical clinical trial (2012) J Anxiety Disord, 26 (1), pp. 25-31
- Diniz, J.B., Shavitt, R.G., Fossaluza, V., Koran, L., de Braganca Pereira, C.A., Miguel, E.C., A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder (2011) J Clin Psychopharmacol, 31 (6), pp. 763-768
- Jakubovski, E., Diniz, J.B., Valério, C., Clinical predictors of long-term outcome in obsessive-compulsive disorder (2013) Depress Anxiety, 30 (8), pp. 763-772
- Costa, D.L., Diniz, J.B., Miguel, E.C., How similar are the disorders included under the umbrella of obsessivecompulsive disorder and related disorders? (2016) JAMA Psychiatry, 73 (8), p. 877
- Foa, E.B., Simpson, H.B., Liebowitz, M.R., Six-month follow-up of a randomized controlled trial augmenting serotonin reuptake inhibitor treatment with exposure and ritual prevention for obsessive-compulsive disorder (2013) J Clin Psychiatry, 74 (5), pp. 464-469
- Simpson, H.B., Foa, E.B., Liebowitz, M.R., Cognitivebehavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: A randomized clinical trial (2013) JAMA Psychiatry, 70 (11), pp. 1190-1199
- Keuthen, N.J., Tung, E.S., Reese, H.E., Raikes, J., Lee, L., Mansueto, C.S., Getting the word out: Cognitivebehavioral therapy for trichotillomania (hair-pulling disorder) and excoriation (skin-picking) disorder (2015) Ann Clin Psychiatry, 27 (1), pp. 10-15
- Williams, M., Viscusi, J.A., Hoarding disorder and a systematic review of treatment with cognitive behavioral therapy (2016) Cogn Behav Ther, 45 (2), pp. 93-110
- Pampaloni, I., Sivakumaran, T., Hawley, C., Highdose selective serotonin reuptake inhibitors in OCD: A systematic retrospective case notes survey (2010) J Psychopharmacol, 24 (10), pp. 1439-1445
- Math, S., Janardhan Reddy, Y., Issues in the pharmacological treatment of obsessive-compulsive disorder (2007) Int J Clin Pract, 61 (7), pp. 1188-1197
- Simeon, J., Thatte, S., Wiggins, D., Treatment of adolescent obsessive-compulsive disorder with a clomipraminefluoxetine combination (1990) Psychopharmacol Bull, 26 (3), pp. 285-290
- Browne, M., Horn, E., Jones, T., The benefits of clomipramine-fluoxetine combination in obsessive compulsive disorder (1993) Can J Psychiatry, 38 (4), pp. 242-243
- Diniz, J.B., Shavitt, R.G., Pereira, C.A.B., Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: A randomized, openlabel trial (2010) J Psychopharmacol, 24 (3), pp. 297-307
- Ravizza, L., Barzega, G., Bellino, S., Bogetto, F., Maina, G., Drug treatment of obsessive-compulsive disorder (OCD): Long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs) (1996) Psychopharmacol Bull, 32 (1), pp. 167-173
- Pallanti, S., Quercioli, L., Paiva, R., Koran, L., Citalopram for treatment-resistant obsessive-compulsive disorder (1999) Eur Psychiatry, 14 (2), pp. 101-106
- Marazziti, D., Golia, F., Consoli, G., Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patients (2008) CNS Spectr, 13 (11), pp. 971-976
- Andrade, C., Augmenting selective serotonin reuptake inhibitors with clomipramine in obsessive-compulsive disorder: Benefits and risks (2013) J Clin Psychiatry, 74 (12), pp. e1128-e1133
- Diniz, J.B., Costa, D.L., Cassab, R.C., Pereira, C.A., Miguel, E.C., Shavitt, R.G., The impact of comorbid body dysmorphic disorder on the response to sequential pharmacological trials for obsessive-compulsive disorder (2013) J Psychopharmacol, 28 (6), pp. 603-611
- Trivedi, M.H., Fava, M., Wisniewski, S.R., Medication augmentation after the failure of SSRIs for depression (2006) N Engl J Med, 354 (12), pp. 1243-1252
- Alevizos, B., Lykouras, L., Zervas, I., Christodoulou, G., Risperidone-induced obsessive-compulsive symptoms: A series of six cases (2002) J Clin Psychopharmacol, 22 (5), pp. 461-467
- Alevizos, B., Papageorgiou, C., Christodoulou, G., Obsessive-compulsive symptoms with olanzapine (2004) Int J Neuropsychopharmacol, 7 (3), pp. 375-377
- Ercan, E.S., Ardic, U.A., Ercan, E., Yuce, D., Durak, S., A promising preliminary study of aripiprazole for treatment-resistant childhood obsessive-compulsive disorder (2015) J Child Adolesc Psychopharmacol, 25 (7), pp. 580-584
- Bloch, M., Landeros-Weisenberger, A., Kelmendi, B., Coric, V., Bracken, M., Leckman, J., A systematic review: Antipsychotic augmentation with treatment refractory obsessive-compulsive disorder (2006) Mol Psychiatry, 11 (7), pp. 622-632
- Albert, U., Carmassi, C., Cosci, F., Role and clinical implications of atypical antipsychotics in anxiety disorders, obsessive-compulsive disorder, trauma-related, and somatic symptom disorders: A systematized review (2016) Int Clin Psychopharmacol, 31 (5), pp. 249-258
- Kim, C., Koo, M., Cheon, K., Ryu, Y., Lee, J., Lee, H., Dopamine transporter density of basal ganglia assessed with [123I]IPT SPET in obsessive-compulsive disorder (2003) Eur J Nucl Med Mol Imaging, 30 (12), pp. 1637-1643
- van der Wee, N., Stevens, H., Hardeman, J., Enhanced dopamine transporter density in psychotropic-naive patients with obsessive-compulsive disorder shown by [123I]{beta}-CIT SPECT (2004) Am J Psychiatry, 161 (12), pp. 2201-2206
- Cheon, K.A., Ryu, Y.H., Namkoong, K., Kim, C.H., Kim, J.J., Lee, J.D., Dopamine transporter density of the basal ganglia assessed with [123I]IPT SPECT in drug-naïve children with Tourette’s disorder (2004) Psychiatry Res, 130 (1), pp. 85-95
- Winogrodzka, A., Bergmans, P., Booij, J., van Royen, E.A., Stoof, J.C., Wolters, E.C., [(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson’s disease (2003) J Neurol Neurosurg Psychiatry, 74 (3), pp. 294-298
- Dell’Osso, B., Altamura, A.C., Allen, A., Marazziti, D., Hollander, E., Epidemiologic and clinical updates on impulse control disorders: A critical review (2006) Eur Arch Psychiatry Clin Neurosci, 256 (8), pp. 464-475
- Denys, D., Klompmakers, A., Westenberg, H., Synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine (2004) Psychopharmacology (Berl), 176 (2), pp. 195-203
- Zhang, W., Perry, K., Wong, D., Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex (2000) Neuropsychopharmacology, 23 (3), pp. 250-262
- McDougle, C., Goodman, W., Leckman, J., Lee, N., Heninger, G., Price, L., Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics (1994) Arch Gen Psychiatry, 51 (4), pp. 302-308
- McDougle, C., Goodman, W., Price, L., Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder (1990) A m J Psychiatry, 147 (5), pp. 652-654
- Srour, M., Lespérance, P., Richer, F., Chouinard, S., Psychopharmacology of tic disorders (2008) J Can Acad Child Adolesc Psychiatry, 17 (3), pp. 150-159
- Van Ameringen, M., Mancini, C., Oakman, J.M., Farvolden, P., The potential role of haloperidol in the treatment of trichotillomania (1999) J Affect Disord, 56 (2-3), pp. 219-226
- Dold, M., Aigner, M., Lanzenberger, R., Kasper, S., Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: An update meta-analysis of doubleblind, randomized, placebo-controlled trials (2015) Int J Neuropsychopharmacol, 18 (9). , pii: pyv047
- Van Ameringen, M., Mancini, C., Patterson, B., Bennett, M., Oakman, J., A randomized, doubleblind, placebo-controlled trial of olanzapine in the treatment of trichotillomania (2010) J Clin Psychiatry, 71 (10), pp. 1336-1343
- Rothbart, R., Stein, D.J., Pharmacotherapy of trichotillomania (hair pulling disorder): An updated systematic review (2014) Expert Opin Pharmacother, 15 (18), pp. 2709-2719
- Turner, G.A., Sutton, S., Sharma, A., Augmentation of venlafaxine with aripiprazole in a case of treatmentresistant excoriation disorder (2014) Innov Clin Neurosci, 11 (1-2), pp. 29-31
- Luca, M., Vecchio, C., Luca, A., Calandra, C., Haloperidol augmentation of fluvoxamine in skin picking disorder: A case report (2012) J Med Case Rep, 6, p. 219
- Phillips, K.A., Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder (2005) Am J Psychiatry, 162 (2), pp. 377-379
- Phillips, K.A., Olanzapine augmentation of fluoxetine in body dysmorphic disorder (2005) Am J Psychiatry, 162 (5), pp. 1022-1023
- Nakaaki, S., Murata, Y., Furukawa, T.A., Efficacy of olanzapine augmentation of paroxetine therapy in patients with severe body dysmorphic disorder (2008) Psychiatry Clin Neurosci, 62 (3), p. 370
- Matsunaga, H., Nagata, T., Hayashida, K., Ohya, K., Kiriike, N., Stein, D., A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder (2009) J Clin Psychiatry, 70 (6), pp. 863-868
- Cortese, B., Phan, K., The role of glutamate in anxiety and related disorders (2005) CNS Spectr, 10 (10), pp. 820-830
- Bhattacharyya, S., Chakraborty, K., Glutamatergic dysfunction: Newer targets for anti-obsessional drugs (2007) Recent Pat CNS Drug Discov, 2 (1), pp. 47-55
- Stewart, S., Fagerness, J., Platko, J., Association of the SLC1A1 glutamate transporter gene and obsessivecompulsive disorder (2007) Am J Med Genet B Neuropsychiatr Genet, 144B (8), pp. 1027-1033
- Qin, H., Samuels, J.F., Wang, Y., Whole-genome association analysis of treatment response in obsessive-compulsive disorder (2016) Mol Psychiatry, 21 (2), pp. 270-276
- Pittenger, C., Glutamate modulators in the treatment of obsessive-compulsive disorder (2015) Psychiatr Ann, 45 (6), pp. 308-315
- Afshar, H., Roohafza, H., Mohammad-Beigi, H., N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: A randomized, doubleblind, placebo-controlled trial (2012) J Clin Psychopharmacol, 32 (6), pp. 797-803
- Paydary, K., Akamaloo, A., Ahmadipour, A., Pishgar, F., Emamzadehfard, S., Akhondzadeh, S., N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: Randomized, doubleblind, placebo-controlled trial (2016) J Clin Pharm Ther, 41 (2), pp. 214-219
- Sarris, J., Oliver, G., Camfield, D.A., N-acetyl cysteine (NAC) in the treatment of obsessivecompulsive disorder: A 16-week, double-blind, randomised, placebo-controlled study (2015) CNS Drugs, 29 (9), pp. 801-809
- Grant, J.E., Odlaug, B.L., Kim, S.W., N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: A double-blind, placebo-controlled study (2009) Arch Gen Psychiatry, 66 (7), pp. 756-763
- Grant, J.E., Chamberlain, S.R., Redden, S.A., Leppink, E.W., Odlaug, B.L., Kim, S.W., N-acetylcysteine in the treatment of excoriation disorder: A randomized clinical trial (2016) JAMA Psychiatry, 73 (5), pp. 490-496
- Donegan, S., Dixon, P., Hemming, K., Tudur-Smith, C., Marson, A., A systematic review of placebo-controlled trials of topiramate: How useful is a multiple-indications review for evaluating the adverse events of an antiepileptic drug? (2015) Epilepsia, 56 (12), pp. 1910-1920
- Shank, R.P., Gardocki, J.F., Streeter, A.J., Maryanoff, B.E., An overview of the preclinical aspects of topiramate: Pharmacology, pharmacokinetics, and mechanism of action (2000) Epilepsia, 41, pp. S3-S9
- Berlin, H., Koran, L., Jenike, M., Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder (2011) J Clin Psychiatry, 72 (5), pp. 716-721
- Jankovic, J., Jimenez-Shahed, J., Brown, L.W., A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome (2010) J Neurol Neurosurg Psychiatry, 81 (1), pp. 70-73
- Lochner, C., Seedat, S., Niehaus, D.J., Stein, D.J., Topiramate in the treatment of trichotillomania: An open-label pilot study (2006) Int Clin Psychopharmacol, 21 (5), pp. 255-259
- Jafferany, M., Osuagwu, F.C., Use of topiramate in skinpicking disorder: A pilot study (2017) Prim Care Companion CNS Disord, 19 (1)
- Jafferany, M., Shireen, F., Ibrahim, A., An open-label trial of topiramate in the treatment of skin picking in pervasive developmental disorder not otherwise specified (2010) Prim Care Companion J Clin Psychiatry, 12 (2). , pii: PCC.09l00829
- Katoh-Semba, R., Asano, T., Ueda, H., Riluzole enhances expression of brain-derived neurotrophic factor with consequent proliferation of granule precursor cells in the rat hippocampus (2002) FASEB J, 16 (10), pp. 1328-1330
- Pittenger, C., Bloch, M.H., Wasylink, S., Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: A pilot randomized placebo-controlled trial (2015) J Clin Psychiatry, 76 (8), pp. 1075-1084
- Emamzadehfard, S., Kamaloo, A., Paydary, K., Riluzole in augmentation of fluvoxamine for moderate to severe obsessive compulsive disorder: Randomized, double-blind, placebo-controlled study (2016) Psychiatry Clin Neurosci, 70 (8), pp. 332-341
- Grant, P.J., Joseph, L.A., Farmer, C.A., 12-week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessivecompulsive disorder (2014) Neuropsychopharmacology, 39 (6), pp. 1453-1459
- Lemmon, M.E., Grados, M., Kline, T., Thompson, C.B., Ali, S.F., Singer, H.S., Efficacy of glutamate modulators in tic suppression: A double-blind, randomized control trial of d-serine and riluzole in Tourette syndrome (2015) Pediatr Neurol, 52 (6), pp. 629-634
- Coric, V., Kelmendi, B., Pittenger, C., Wasylink, S., Bloch, M.H., Green, J., Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with trichotillomania (2007) J Clin Psychiatry, 68 (1), pp. 170-171
- Sasso, D.A., Kalanithi, P.S., Trueblood, K.V., Beneficial effects of the glutamate-modulating agent riluzole on disordered eating and pathological skin-picking behaviors (2006) J Clin Psychopharmacol, 26 (6), pp. 685-687
- Reid, J.G., Gitlin, M.J., Altshuler, L.L., Lamotrigine in psychiatric disorders (2013) J Clin Psychiatry, 74 (7), pp. 675-684
- Bruno, A., Micò, U., Pandolfo, G., Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: A double-blind, placebo-controlled study (2012) J Psychopharmacol, 26 (11), pp. 1456-1462
- Bloom, R., Amber, K.T., Identifying the incidence of rash, Stevens-Johnson syndrome and toxic epidermal necrolysis in patients taking lamotrigine: A systematic review of 122 randomized controlled trials (2017) An Bras Dermatol, 92 (1), pp. 139-141
- Plosker, G.L., Lyseng-Williamson, K.A., Memantine: A pharmacoeconomic review of its use in moderateto- severe Alzheimer’s disease (2005) Pharmacoeconomics, 23 (2), pp. 193-206
- Ghaleiha, A., Entezari, N., Modabbernia, A., Memantine add-on in moderate to severe obsessive-compulsive disorder: Randomized doubleblind placebo-controlled study (2013) J Psychiatr Res, 47 (2), pp. 175-180
- Bartoli, F., Riboldi, I., Crocamo, C., Di Brita, C., Clerici, M., Carrà, G., Ketamine as a rapid-acting agent for suicidal ideation: A meta-analysis (2017) Neurosci Biobehav Rev, 77, pp. 232-236
- Rodriguez, C.I., Kegeles, L.S., Levinson, A., Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: Proof-of-concept (2013) Neuropsychopharmacology, 38 (12), pp. 2475-2483
- Rodriguez, C.I., Wheaton, M., Zwerling, J., Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder? An openlabel trial (2016) J Clin Psychiatry, 77 (3), pp. 408-409
- Andrade, C., Ondansetron augmentation of serotonin reuptake inhibitors as a treatment strategy in obsessive-compulsive disorder (2015) J Clin Psychiatry, 76 (1), pp. e72-e75
- Askari, N., Moin, M., Sanati, M., Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial (2012) CNS Drugs, 26 (10), pp. 883-892
- Shalbafan, M., Mohammadinejad, P., Shariat, S.V., Celecoxib as an adjuvant to fluvoxamine in moderate to severe obsessive-compulsive disorder: A double-blind, placebo-controlled, randomized trial (2015) Pharmacopsychiatry, 48 (4-5), pp. 136-140
- Koran, L., Aboujaoude, E., Bullock, K., Franz, B., Gamel, N., Elliott, M., Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder (2005) J Clin Psychiatry, 66 (3), pp. 353-359
- Hamon, M., Blier, P., Monoamine neurocircuitry in depression and strategies for new treatments (2013) Prog Neuropsychopharmacol Biol Psychiatry, 45, pp. 54-63
- Kennedy, S.H., Rizvi, S.J., Emerging drugs for major depressive disorder (2009) Expert Opin Emerg Drugs, 14 (3), pp. 439-453
- Grados, M., Prazak, M., Saif, A., Halls, A., A review of animal models of obsessive-compulsive disorder: A focus on developmental, immune, endocrine and behavioral models (2016) Expert Opin Drug Discov, 11 (1), pp. 27-43
- Cobb, J., Behaviour therapy in phobic and obsessional disorders (1983) Psychiatr Dev, 1 (4), pp. 351-365
- Manos, R.C., Cahill, S.P., Wetterneck, C.T., Conelea, C.A., Ross, A.R., Riemann, B.C., The impact of experiential avoidance and obsessive beliefs on obsessivecompulsive symptoms in a severe clinical sample (2010) J Anxiety Disord, 24 (7), pp. 700-708
- Katz, D., Rector, N.A., Laposa, J.M., The interaction of distress tolerance and intolerance of uncertainty in the prediction of symptom reduction across CBT for social anxiety disorder (2017) Cogn Behav Ther, pp. 1-19
- Costa, D.L.D.C., Barbosa, V.S., Requena, G., Shavitt, R.G., Pereira, C.A.B., Diniz, J.B., Dissecting the Yale-Brown Obsessive-Compulsive Scale severity scale to understand the routes for symptomatic improvement in obsessive-compulsive disorder (2017) J Psychopharmacol, 31 (10), pp. 1312-1322
- Conceição, C.D.L., Chagas, A.M., Arzeno, F.Y., Body dysmorphic disorder in patients with obsessivecompulsive disorder: Prevalence and clinical correlates (2012) Depress Anxiety, 29 (11), pp. 966-975
- Kelly, M.M., Walters, C., Phillips, K.A., Social anxiety and its relationship to functional impairment in body dysmorphic disorder (2010) Behav Ther, 41 (2), pp. 143-153
- (2013) Diagnostic and Statistical Manual of Mental Disorders, , 5th ed. Washington, DC: APA
- Bohne, A., Savage, C.R., Deckersbach, T., Keuthen, N.J., Wilhelm, S., Motor inhibition in trichotillomania and obsessive-compulsive disorder (2008) J Psychiatr Res, 42 (2), pp. 141-150
- Chamberlain, S., Odlaug, B., Boulougouris, V., Fineberg, N., Grant, J., Trichotillomania: Neurobiology and treatment (2009) Neurosci Biobehav Rev, 33 (6), pp. 831-842
- Christenson, G.A., Mackenzie, T.B., Trichotillomania, body dysmorphic disorder, and obsessive-compulsive disorder (1995) J Clin Psychiatry, 56 (5), pp. 211-212
- Arnold, L., Auchenbach, M., McElroy, S., Psychogenic excoriation. Clinical features, proposed diagnostic criteria, epidemiology and approaches to treatment (2001) CNS Drugs, 15 (5), pp. 351-359
- McGuire, J.F., Wu, M.S., Piacentini, J., McCracken, J.T., Storch, E.A., A meta-analysis of d-cycloserine in exposure-based treatment: Moderators of treatment efficacy, response, and diagnostic remission (2017) J Clin Psychiatry, 78 (2), pp. 196-206
- Song, C., Stevenson, C.W., Guimarães, F.S., Lee, J.L., Bidirectional effects of cannabidiol on contextual fear memory extinction (2016) Front Pharmacol, 7, p. 493
- Jurkus, R., Day, H.L., Guimarães, F.S., Lee, J.L., Bertoglio, L.J., Stevenson, C.W., Cannabidiol regulation of learned fear: Implications for treating anxietyrelated disorders (2016) Front Pharmacol, 7, p. 454
- Wang, Y., Zhang, X., FAAH inhibition produces antidepressant-like efforts of mice to acute stress via synaptic long-term depression (2017) Behav Brain Res, 324, pp. 138-145